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Abstract
Background: The transcription factor Forkhead box A1 (FOXA1) is suggested to be important in hormone dependent
cancers, although with little data for endometrial cancer. We investigated expression levels of FOXA1 in primary and
metastatic endometrial cancer in relation to clinical phenotype, and transcriptional alterations related to FOXA1 status.
Methods: Protein expression of FOXA1 was explored by immunohistochemistry in 529 primary and 199 metastatic
endometrial carcinoma lesions. mRNA levels from corresponding 158 fresh frozen primary and 42 metastatic lesions were
analyzed using Agilent Microarrays (44k) in parallel.
Results: Low FOXA1 protein expression in primary tumors significantly correlated with low FOXA1 mRNA, high age, non-
endometrioid histology, high grade, loss of ERa and PR and poor survival (all p-values ,0.05). Through a Connectivity Map
search, HDAC inhibitors were suggested as potential treatment for patients with low FOXA1 expression. An increase in
FOXA1 expression was observed from primary to metastatic lesions and it correlated with CDKN2A expression in
metastases.
Conclusion: Low FOXA1 is associated with poor survival and suggests a potential for HDAC inhibitors in endometrial
carcinoma. A switch in FOXA1 expression from primary to metastatic lesions is observed and gene expression indicates a
link between FOXA1 and CDKN2A in metastatic lesions.
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Introduction
In the Western world endometrial cancer is the most common
gynecological malignancy, and the incidence is rising [1].
Endometrial cancers are broadly classified in two groups. Type I
endometrial cancer is most common and is characterized by
favorable outcome, endometrioid histology, low stage and grade
and often intact expression of hormone receptors. Type II
endometrial cancer is associated with poor outcome, non-
endometrioid histology, high stage and grade, and has usually
lost expression of hormone receptors [2]. Patients are standardly
surgically treated with hysterectomy with bilateral salpingoophor-
ectomy with or without lymphadenectomy. The effect of adjuvant
systemic treatment is less studied for endometrial compared to
ovarian cancer, although similar platinum based chemotherapy
regimens in combination with paclitaxel often is used in the
adjuvant and systemic disease setting.
Estrogen dependent endometrial cancers are thought to arise
from prolonged unopposed exposure to estrogens. Estrogen
dependent activation of estrogen receptor a (ERa) has been
reported to lead to proliferation through upregulation of growth
factors such as epidermal growth factor (EGF) [3], its receptor
EGFR [4], insulin like growth factor (IGF-1) [5] and growth
enhancing proto-oncogenes like c-myc [6]. Regulation of ERa
activity is also known to involve several cofactors including both
coactivators and corepressors. In addition the pioneer factor
Forkhead box A1 (FOXA1) has been shown to be an important
regulator of ERa activity through facilitating binding of ERa [7].
FOXA1 is a member of the Forkhead Box transcription factor
family, formerly known as Hepatocyte Nuclear Factor (HNF)
family. FOXA1 proteins bind DNA and induce nucleosomal
rearrangement that often results in an open chromatin structure
[8,9]. This facilitates the binding of additional transcription
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factors, including ERa [7]. FOXA1 has been found to be recruited
to almost half of all ER binding regions [7].
The association between hormone receptors and known
prognostic variables such as FIGO stage, histologic grade and
survival has been well documented in endometrial carcinoma [10–
12]. More knowledge regarding molecular mechanisms involved
in estrogen signaling and estrogen-related cofactors in hormone
related cancers is needed to develop new therapeutic strategies.
Several studies have suggested a role for FOXA1 in different
hormone dependent cancers [13]. High FOXA1 expression is
correlated with good prognosis in ER positive breast cancer but in
prostate cancer FOXA1 level has been associated with either good
or bad prognosis depending on the patient group, and has been
proposed as a context dependent marker for survival in hormone
dependent cancers [14–17].
Furthermore, the association between FOXA1 and ER in breast
cancer and FOXA1 and androgen receptor (AR) in prostate
cancer suggests that expression levels of FOXA1 may influence
responsiveness to antihormonal treatment in hormone dependent
cancers. On this background, we investigated the expression level
of FOXA1 in endometrial cancer in relation to phenotype and
established biomarkers including hormone receptor status; and
subsequently explore transcriptional alterations related to FOXA1
protein levels in primary and metastatic endometrial carcinoma
lesions.
Materials and Methods
Ethics statement
All parts of the study have been approved according to
Norwegian legislation. The study was approved by the Norwegian
Data Inspectorate, Norwegian Social Sciences Data Services and
the Regional Committee for Medical Research Ethics, REC West
(NSD15501; REK 052.01). All participants gave written informed
consent.
Patient series
A population based patient series, including 529 patients
diagnosed with endometrial cancer in Hordaland County (Nor-
way) during the period from 2001–2011, was studied. Tissue from
primary tumors was included prospectively from consented
patients surgically staged according to the International Federa-
tion of Gynaecology and Obstetrics (FIGO) 2009 criteria. The
clinicopathological variables, age at diagnosis, FIGO stage,
histological subtype and grade, treatment and follow-up were
collected by review of medical records as reported earlier [18]. For
91 patients with advanced or recurrent disease, biopsies were
available from metastatic tissue (a total of 199 FFPE lesions). Fresh
frozen tissue (158 primary and 42 metastatic lesions) was collected
and prepared in parallel with the formalin-fixed paraffin
embedded tissues (FFPE) when available.
Tissue microarrays
Tissue microarrays (TMAs) were prepared from FFPE tissue
from primary tumors and metastases. The area of highest tumor
grade was identified on hematoxylin and eosin stained slides.
Three tissue cylinders from primary tumors, and one tissue
cylinder from metastases (0.6 mm) were punched out from
selected areas, and mounted in a recipient paraffin block using a
custom made precision instrument (Beecher instruments, Silver
Spring, MD, USA). This method for producing TMAs has
previously been described and validated [19].
Immunohistochemistry
Five mm thick TMA sections were dewaxed with xylene and
rehydrated in graded ethanol series. For FOXA1 detection,
antigen retrieval was performed by microwave boiling for 20
minutes in citrate buffer (pH 6). Endogenous peroxidase and
nonspecific binding of primary antibody were blocked with
peroxidase block (S2023, Dako, Denmark) and serum free protein
block (X0909, Dako, Denmark). Slides were incubated with anti-
FOXA1 primary antibody (ab23738, Abcam, UK), diluted 1:800,
for 30 minutes at room temperature. Secondary antibody,
combined anti-mouse and anti-rabbit (K5007, Dako, Denmark),
was applied for 30 minutes, followed by 8 minutes with
Diaminobenzidine (DAB+, K4007, Dako, Denmark) before
counterstaining with hematoxylin. Immunohistochemical staining
of ERa has previously been described for 477 primary tumors and
78 metastases. Additional 92 primary tumors were stained
according to the method reported previously [12].
Evaluation of staining
IHC staining was evaluated using a semiquantitative system
where both intensity of the staining, and area of tumor cells with
positive staining were considered. Staining intensity was graded
from 0 (no staining) to 3 (strong staining). Proportion of stained
tumor cells was graded as 0, 1 (,10%), 2 (10% to 50%) and 3 (.
50%). A staining index was calculated as the product of intensity
and staining area. In the statistical analysis, staining indexes for
FOXA1 were categorized in tertiles considering the frequency
distribution for the marker, size of subgroups and the number of
events in each category. The two lower tertiles, showing similar
survival estimates, were subsequently merged. Cut-off value for
ERa was applied as previously defined [12]. To evaluate the
reproducibility, two independent observers (ILT and CK) scored
random TMA slides, giving k-value of 0.80 for FOXA1 and 0.82
for ERa [12]. When evaluating heterogenic multiple metastatic
lesions form the same patient, FOXA1 was defined as low if any of
the metastatic lesions demonstrated low expression.
Microarray analysis
Freshly frozen tissues from 158 primary tumors and 42
metastases were collected in parallel with the FFPE tissues.
Extraction of RNA was done using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). RNA was hybridized to Agilent Whole Human
Genome Microarrays 44k (Cat. no. G4112F) according to the
manufacturer’s instruction, and the arrays were scanned using the
Agilent Microarray Scanner Bundle. The J-express software
(Molmine, Bergen, Norway) was used to analyze the data. Median
spot signal was used as intensity measure and expression data were
normalized using quantile normalization. Microarray data have
been deposited in the ArrayExpress Archive database, http://
www.ebi.ac.uk/arrayexpress/with the Accession Number E-
MTAB-2532. Genes differentially expressed between groups were
identified by SAM (Significance Analysis of Microarray) analysis
and were considered significant if False Discovery Rate (FDR),
0.01. If the number of samples did not allow the use of SAM, FSS
(Feature Subset Selection) analysis was used and P,0.01 was
considered significant.
Connectivity Map
Correlation between gene expression and potential therapeutics
was investigated using the drugs signature database Connectivity
Map [20]. The drug signatures in this database is generated by
genes differentially expressed in cell lines treated with drugs
compared to untreated cell lines, and reflect the genes presumed to
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be altered by the drug. Genes differentially expressed according to
FOXA1 status, both within the whole patient population and
within the ERa negative group were the basis for analysis in
Connectivity Map.
Statistical analysis
The software package SPSS 19.0 (SPSS Inc, Chicago, IL) was
used for statistical analyses. Statistical significance was defined as
probability ,0.05. Association between groups was evaluated
using the Pearson x2 test for categorical variables. Univariate
survival analysis was performed using the Kaplan-Meier (product-
limit) method with date of primary surgery as entry date and time
to death due to endometrial carcinoma as endpoint (disease
specific survival). Patients who died from other causes were
censored at the date of death. The log-rank test (Mantel-Cox) was
used to compare survival between groups. The Cox proportional
hazard regression model was used to evaluate the prognostic
impact of FOXA1 adjusted for other prognostic markers in
endometrial cancer. Due to an interaction between FIGO stage
and histologic type, Cox analysis was performed in the endome-
trioid subtype.
Results
Low FOXA1 expression is associated with poor prognosis
in endometrial cancer
FOXA1 has previously been shown to be a pioneer factor for
ER in breast cancer (Figure S1). We investigated a large and
unique collection of endometrial cancer samples to elucidate a
potential similar role for FOXA1 in these diseases. Protein
expression of FOXA1 was primarily nuclear. The protein
expression was seen both in stromal and glandular tissues, but
only staining in the nuclei of glandular tissue was scored. When
comparing FOXA1 status with available clinicopathological
variables, low FOXA1 expression (score index from 0–4) was
significantly correlated with high age (P= 0.04), non-endometrioid
histology (P= 0.002), high histologic grade (P= 0.003), loss of PR
(P= 0.02) and ERa (P = 0.003) (Table 1). Low FOXA1 protein
expression was significantly associated with reduced disease
specific survival (P = 0.004) (Figure 1A) and low FOXA1 mRNA
expression (P= 0.001) (Figure 1B). For patients with ERa positive
tumors, we found no impact of FOXA1 (Figure 2A) in contrast to
the ERa negative group where low FOXA1 expression was
significantly associated with worse outcome (Figure 2B). In a
multivariate analysis, in the endometrioid subgroup, using the Cox
proportional hazard model with age, FIGO stage, histologic grade,
FOXA1 and ERa expression as variables, FOXA1 expression was
found to have prognostic impact similar to grade and ERa status,
although with no independent prognostic impact (Table S1).
Gene expression related to FOXA1 and ERa expression
does not overlap
As for breast cancer, ERa loss has been consistently associated
with poor survival in patients with endometrial cancer [2,11,12].
As FOXA1 is shown to be important for ERa-chromatin
interactions in breast cancer, we further investigated whether
FOXA1 related gene expression resembles ERa regulated gene
expression in endometrial cancer. SAM analysis identified 468
genes differentially expressed in tumors with intact ERa expression
compared to loss, while 506 genes were differentially expressed in
tumors with high FOXA1 expression compared to low. Only three
overlapping genes were identified in the ERa and FOXA1 related
gene lists (Table S2 and S3).
HDAC inhibitors are suggested as potential drugs for
treatment of endometrial cancers with low FOXA1
Genes differentially expressed related to FOXA1 status were
used to query Connectivity Map for compounds with potential to
revert the gene signature of patients with low FOXA1 status. Two
HDAC inhibitors came up among the top five ranked compounds
(Table 2). These two HDAC inhibitors were also the two top
ranked anticorrelated compounds to low FOXA1 expression
within the ERa negative patient subgroup (Table 2) (Table S4).
Metastatic spread is associated with a shift in FOXA1
expression
Metastatic lesions from 91 patients were stained for FOXA1
expression to investigate FOXA1 status in metastatic lesions.
When defining FOXA1 as low if any of the metastatic lesions
demonstrated low expression, no significant change in expression
was seen between the whole population of primary tumors and the
metastatic lesions (Figure 3A). Surprisingly, when comparing
FOXA1 levels for primary tumors from patients with systemic
disease with their metastatic lesion counterparts, expression of
FOXA1 was found to be significantly higher in the metastatic
lesions compared to the corresponding primary lesion. This was
also true when all metastatic lesions, independent of the number of
metastases per patient, were examined (Figure 3B). We have
previously found that there is a significant loss of expression of
ERa from primary to metastatic lesions [12]. When comparing
FOXA1 and ERa expression in metastatic lesion no correlation
between the expression levels was found (r2 = 0.012) (Figure 3C).
The same was observed when comparing FOXA1 levels in
metastases from only ERa positive primary endometrial tumors
(r2 = 0.11) (Figure 3D).
FOXA1 and CDKN2A levels are linked in metastatic
lesions
To investigate differences in transcriptional effects related to
FOXA1 levels in primary and metastatic lesions we further
explored genes differentially expressed according to FOXA1 status
in primary tumors compared to metastases (Table S3 and S5). The
overlap between the genes differentially expressed was low (only 26
genes). Interestingly, one of the top ranked genes differentially
expressed according to FOXA1 protein expression in metastatic
lesions was CDKN2A. FOXA1 was recently shown to control
CDKN2A expression [21]. To investigate whether this association
was limited to the metastatic setting, we investigated a potential
link between FOXA1 and CDKN2A also in primary tumors
(Figure 4). A significant association between FOXA1 and
CDKN2A was only observed in metastatic lesions.
Discussion
FOXA1 has been recognized as an important transcription
factor that modulates the functions of steroid receptors such as
estrogen receptor in breast cancer and AR in prostate cancer.
FOXA1 as a prognostic marker in breast cancer has been
extensively studied [14,22], and high expression of FOXA1 is
correlated with better disease specific survival, ERa positivity and
the luminal subtype A. In prostate cancer high expression of
FOXA1 predicts poor prognosis, and correlates with AR positivity
[15]. Also, the recent publication by The Cancer Genome Atlas
(TCGA) Research Network showed low ER/FOXA1 signaling to
be associated with poor survival in endometrial cancer [23]. Our
findings that low FOXA1 expression is significantly associated with
markers for worse outcome as well as poor survival appear to be in
FOXA1 and Endometrial Cancer
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line with the TCGA data and findings in breast cancer, but in
contrast to prostate cancer and one previous small, and potentially
underpowered study of 109 endometrial carcinoma cases showing
no significant prognostic impact of FOXA1 expression [24].
In breast cancer cells FOXA1 has been shown to be necessary
for estrogen response [7]. Similar to breast cancer, endometrial
cancer is an estrogen dependent cancer and type 1 endometrial
cancer is associated with expression of ERa. ERa positive patients
have a significantly better survival than patients with ERa loss and
ERa is a strong prognostic marker in endometrial cancer [2].
Studies in breast cancer have shown that ERa positive patients
with high expression of FOXA1 have a significantly better survival
compared to patients with low expression of FOXA1 [14,25]. We
could not find a similar strong survival effect for FOXA1 within
the ERa positive group, but only within the ERa negative group of
patients. If the reduced survival observed for the FOXA1 negative
group only was due to loss of ERa a significant association
between FOXA1 and survival within the ERa negative group
would not have been expected. This could indicate that FOXA1 in
endometrial cancer may have a function that is not linked to ERa,
and the effect of FOXA1 could be organ specific. FOXA1 has
previously been shown to regulate distinct transcriptional pro-
grams in cells of different linages [26], and the clinical experience
with increased endometrial cancer risk amongst women with ERa
positive breast cancers treated with Tamoxifen also supports organ
specific differences in the hormone regulation. Further supporting
this, gene expression related to FOXA1 levels did not overlap with
expression pattern related to ERa. If FOXA1 is important for
regulating ERa activity in endometrial cancer, as is seen in breast
cancer, an overlap between the differentially expressed genes
would be expected. In addition, our data suggest HDAC inhibitors
as potential treatment for patients with low FOXA1 expression,
both within the whole patient population and within the ERa
negative group. This is interesting, as PI3K and mTOR inhibitors
Figure 1. FOXA1 and survival. (A) Kaplan-Meier curve showing disease specific survival according to FOXA1 protein level. Low FOXA1 expression
is significantly correlated with reduced survival for patients with endometrial carcinoma. Left and right insert shows low and high nuclear expression
of FOXA1 respectively. (B) Low protein expression of FOXA1 is significantly correlated with low FOXA1 mRNA expression.
doi:10.1371/journal.pone.0098069.g001
Figure 2. FOXA1 survival analyses stratified for ERa status in the tumors. (A) Low FOXA1 expression among ERa positive patients did not
significantly impact survival. (B) Amongst ERa negative patients FOXA1 expression significantly influenced survival with worst prognosis for patients
with low FOXA1.
doi:10.1371/journal.pone.0098069.g002
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Table 1. FOXA1 protein expression in 529 patients with endometrial carcinoma related to clinicopathologic variables
FOXA1
Variable High n (%) Low n (%) P-value
Age 0.04
,66 118 (42) 160 (58)
$66 85 (34) 166 (66)
FIGO-09 stage 0.06
I–II 176 (40) 262 (60)
III–IV 27 (30) 64 (70)
Histologic type 0.002
Endometrioid* 180 (42) 254 (58)
Non-endometrioid 23 (24) 72 (76)
Histologic grade 0.003
Grade 1/2 149 (43) 199 (57)
Grade 3 52 (29) 125 (70)
Metastatic nodes 0.07
Negative 165 (43) 215 (57)
Positive 16 (30) 37 (70)
Ploidy 0.06
Diploid 111 (40) 170 (60)
Aneuploid 21 (28) 55 (72)
ERa 0.003
Positive 166 (42) 227 (58)
Negative 34 (27) 90 (73)
PR 0.02
Positive 124 (39) 197 (61)
Negative 29 (27) 80 (73)
Missing: histologic grade: 4, metastatic nodes: 96, ploidy: 172, ERa: 12, PR: 99.
Abbreviations: ERa= estrogen receptor a; PR = progesterone receptor. P-values based on the Chi-square test. *Endomterioid carcinomas including cases with areas with
squamous cell differentiation but no pure squamous cell carcinomas; Non-endometrioid subtype included serous, clear cell, undifferentiated histologies and
carcinosarcomas.
doi:10.1371/journal.pone.0098069.t001
Table 2. Top ranked drugs and targets for therapy related to FOXA1 status, based on Connectivity Map
Drug signatures negatively correlated to endometrial cancer with low FOXA1 expression
Rank Name of compound Description na Pb
1 Semustine Alkylating agent{ 4 ,0.001
2 Withaferin A Angiogenesis inhibitor [31] 4 ,0.001
3 Vorinostat HDAC inhibitor* 12 ,0.001
4 Thioridazine Protein kinase inhibitor* 20 ,0.001
5 Trichostatin A HDAC inhibitor* 182 ,0.001
Drug signatures negatively correlated to ERa negative endometrial cancer with low FOXA1 expression
1 Vorinostat HDAC inhibitor* 12 ,0.001
2 Trichostatin A HDAC inhibitor* 182 ,0.001
3 Thioridazine Protein kinase inhibitor* 20 ,0.001
4 Ciclosporin Immunosuppressive [32] 6 ,0.001
5 5707885 4 ,0.001
{Function as described Martindale monograph.
*Function as described in ChemBank (http://chembank.broadinstitute.org/).
Na number of instances in which the compounds were tested in Connectivity map.
Pb The p-value for each compound represents the distribution of these scores compared with the distribution of scores among all small molecules, using a permutation
test as described by Lamb et al [20].
doi:10.1371/journal.pone.0098069.t002
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Figure 3. Increased expression of FOXA1 in metastases. (A) FOXA1 expression is retained from primary tumors to metastases, while the
expression is significantly increased from paired primary tumors to their corresponding metastases. FOXA1 is defined as low if any of the metastatic
lesions from the individual cases explored (n = 78) demonstrated low expression. (B) Looking at all metastases (n = 199) there is a significant increase
in expression from primary to metastatic lesions. Numbers indicate number of cases investigated with number of cases with high expression in
parenthesis. (C) There is no correlation between FOXA1 and ERa expression in metastases and the correlation between FOXA1 and ERa expression in
metastases only from ERa positive primary tumors is low (D).
doi:10.1371/journal.pone.0098069.g003
Figure 4. FOXA1 and CDKN2A. Protein expression of FOXA1 is significantly associated with CDKN2A mRNA expression in metastases, but not in
primary tumors.
doi:10.1371/journal.pone.0098069.g004
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recently have been suggested as promising drugs for patients with
ERa negative tumors in particular [11]. The present finding
suggests that FOXA1 involvement in ERa regulation might be
different in endometrial cancer compared to what is found in
breast cancer. This appears to be in line with an endometrial
cancer cell line study demonstrating that introduction of FOXA1
suppresses both proliferation and migration [24] in contrast to
ERa which leads to proliferation. The role of FOXA1 as a pioneer
factor for ERa has also been found to differ in various cancer cell
types. Recruitment to chromatin was shown to be dependent of
FOXA1 in breast cancer cells, however in an osteoblast like cell
line (U2OS-ERa) FOXA1 is not expressed and ERa binding is
independent of FOXA1 [27]. In endometrial cancer, FOXA1 is
important for inhibition of cell proliferation and migration[24],
and in prostate cancer cell lines FOXA1 was recently shown to
inhibit cell motility and epithelial to mesenchymal transition
(EMT) through regulation of the transcription factor SLUG[17].
Little is known regarding bindingpartners for FOXA1 in
endometrial cancer, and more work is needed to elucidate this.
Our finding that FOXA1 protein expression increase from
primary tumors to metastases, could appear as contradictory to
our finding that high FOXA1 associates with good outcome in
patients with endometrial cancer. ERa expression loss has been
reported to increase from primary to metastatic endometrial
carcinoma lesions [12]. The low correlation between ERa and
FOXA1 expression in metastatic lesions, suggests that FOXA1 is
less critical for ERa function in endometrial cancer compared to
what has been observed for breast cancer [28]. In both prostate
and breast cancers high expression of FOXA1 in metastatic lesions
were found, however with retained expression of AR and ERa
respectively [28,29]. Taken together, this suggests that the role of
pioneer factors in regulation of nuclear receptors in hormone
dependent cancers is tissue related. In breast cancer FOXA1
seems important for ER mediated transcription, and silencing of
FOXA1 leads to inhibition of ER binding and transcriptional
activity [30]. In prostate cancer FOXA1 has been found to be a
pioneer factor for AR for some binding events, but also a
repressor. Change in FOXA1 expression in prostate cancer
therefore seems to lead to reprogramming of AR binding events
[15].
The higher expression of FOXA1 in metastases compared to
their primary tumor counterparts, and the association between
protein expression of FOXA1 and CDKN2A mRNA only in
metastatic lesions, may indicate a change in the role of FOXA1
during endometrial cancer progression. Metastases with high
expression of FOXA1 also have high expression of CDKN2A.
CDKN2A is known to encode several distinct proteins, including
p16INK4A, p15INK4B and p14ARF. Interestingly FOXA1 was
recently shown to control p16INK4A expression during cellular
senescence [21]. Which protein encoded by CDKN2A that is
expressed in metastases is however unknown and needs to be
further investigated.
FOXA1 seems to have tissue specific roles that also may change
during endometrial cancer progression. In addition, it is likely that
other unknown factors than FOXA1 is required for regulation of
ERa function in endometrial cancer. Identifying more of these will
improve our understanding of tissue specific hormone receptor
signaling and will be of relevance when developing targeted
therapeutics in ERa related malignant disease, including endo-
metrial cancer. Thus, FOXA1 may add clinically relevant
information as a biomarker in endometrial cancers and points to
a role for HDAC inhibitors for treatment.
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